[Comparison of the clinical efficacy of recombinant tissue-type plasminogen activator thrombolysis with primary coronary stenting in acute myocardial infarction]

Zhonghua Nei Ke Za Zhi. 2002 Jan;41(1):21-3.
[Article in Chinese]

Abstract

Objective: To compare the efficacy of low dose recombinant tissue-type plasminogen activator (rt-PA) thrombolysis with primary coronary stenting after acute myocardial infarction (AMI).

Methods: Of 261 patients with first AMI, 131 patients were performed with low dose rt-PA intravenously, and 130 patients with primary coronary stenting. The clinical efficacy of these two groups was compared.

Results: The age, time from onset of chest pain to hospital presentation and infarct location between these two groups were comparable. The patency rate of infarct-related artery (IRA) in patients with thrombolysis group was significantly lower than that of patients with primary stenting group (P < 0.00001). The recurrent myocardial infarction, selective coronary stenting of patients with thrombolytic therapy were higher than that of patients with primary stenting group (7.6% vs 1.5%, P < 0.05; 20.6% vs 0, P < 0.001, respectively). The LVEF in patients with thrombolysis group was lower than that of stenting group [(55.6 +/- 13.4)% vs (65.8 +/- 9.2)%, P < 0.0001]. Total hospitalization time of thrombolysis group was longer than that of stenting group [(16 +/- 7) days vs (11 +/- 4) days, P < 0.0001]. The mortality of thrombolysis group was higher than that of stenting group, but this difference was not significant (6.1% vs 3.1%, P > 0.05).

Conclusions: Compared with low dose rt-PA thrombolytic therapy after AMI, primary coronary stenting has a higher patency rate of the IRA, better cardiac function and shorter hospitalization time.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • English Abstract

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary
  • Coronary Stenosis / drug therapy*
  • Female
  • Humans
  • Injections, Intravenous
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / therapy
  • Recombinant Proteins / therapeutic use
  • Recurrence
  • Stents
  • Thrombolytic Therapy
  • Tissue Plasminogen Activator / therapeutic use*
  • Treatment Outcome
  • Vascular Patency / physiology

Substances

  • Recombinant Proteins
  • Tissue Plasminogen Activator